Table 1.
Experimental model | Pro-inflammatory agents | Anti-inflammatory agents | Reference |
---|---|---|---|
Primary culture of rat astrocytes treated with Aβ1-42 | ↑TNFα; ↑IL-1β; ↑IL-6; ↑COX-2; ↑PGE2; ↑IL-17; ↑INF-γ; ↑IP-10 | ↑IL-13 | Hu et al., 1998; Akama and Van Eldik, 2000; Garwood et al., 2011; Wang et al., 2013; Aguirre-Rueda et al., 2015 |
Isolated rat astrocytes treated with Aβ25-35 | ↑TNFα; ↑IL-1β | Del Bo et al., 1995; Ayasolla et al., 2004 | |
Primary cultures of rat astrocytes treated with Aβ1-40 | ↑IL-1β; ↑IL-6 | Bales et al., 1998 | |
Mixed cultures of rat neurons and astrocytes treated with Aβ1-42 and Aβ25-35 | ↑TNFα | Masilamoni et al., 2005b | |
Primary cultures of rat astrocytes treated with spherical aggregates of synthetic Aβ | ↑IL-1β | Todd and Garrard, 1979 | |
In vivo i.c. infusion of Aβ1-42 oligomers in rats | ↑IL-1β; ↑TNFα; ↑COX-2 | Carrero et al., 2012 | |
Primary culture of mice astrocytes treated with Aβ1-42 | ↑IL-1β; ↑IL-6; ↑TNFα | ↓TGF-β1 | Liu et al., 2009; Hou et al., 2011 |
Brain sections of Tg2576 mice stained for GFAP | ↑IL-1β; ↑IL-6; ↑INF-γ; ↑IL-12 | ↑TGF- β1; ↑IL-10 | Mehlhorn et al., 2000; Apelt and Schliebs, 2001; Abbas et al., 2002 |
In vivo i.c.v infusion of Aβ1-42 oligomers in mice | ↓TGF-β1 | Diniz et al., 2017 | |
In vivo i.c.v infusion of Aβ1-42 in IL-32β transgenic mice | ↑IP-10; ↑GM-CSF | ↑IL-13 | Yun et al., 2015 |
Astrocytoma human cell line U-373 MG treated with Aβ1-40 (co-treated with IL-1β) | ↑IL-6 | Gitter et al., 1995 | |
Postmortem brain tissue from patients with AD, stained for GFAP (or other astrocytic marker) | ↑IL-1β; ↑IL-6; ↑IL-18 | Ojala et al., 2009; Bouvier et al., 2016 |
TNFα, tumor necrosis factor alpha; TGF-β1, transforming growth factor beta 1; COX-2, cyclooxygenase-2; PGE2, prostaglandin E2; GFAP, glial fibrillary acidic protein; IP-10, interferon gamma-induced protein 10; GM-CSF, granulocyte–macrophage colony-stimulating factor; i.c., intracerebral; i.c.v., intracerebroventricular.